Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

NCT07197307 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

Aggressive Diffuse Large B-cell Lymphoma
High-grade B-cell Lymphoma (HGBL)
Follicular Lymphoma (FL) Grade 3B

Interventions

DRUG: Loncastuximab Tesirine and Epcoritamab

Sponsor

Universität Münster

Collaborators

[object Object]
[object Object]